title: [Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy].
abstract: BACKGROUND
  Treatment of multiple sclerosis has advanced considerably in the last few years, at the same time as its complexity has increased. The purpose of this consensus document is to provide specific recommendations and rules on the strategy to follow in the treatment of multiple sclerosis in order to modify its course.
  
  
  METHODS
  Experts on the treatment and clinical research on multiple sclerosis proposed by the Demyelinating Diseases Group of the Spanish Neurology Society (SEN) prepared an initial document with recommendations for the treatment of this disease. The final version of this document was submitted to members of the Demyelinating Diseases Group of the SEN, who were able to make modifications and suggest changes to the final manuscript.
  
  
  CONCLUSIONS
  A review has been made of the evidence levels and indications for the treatment of the different clinical forms of multiple sclerosis, and recommendations made for the use of drugs. As well as authorised drugs, a review has also been made of other occasionally used products, as well as combined therapy, therapeutic response criteria, levels of treatment changes, and finally a proposal is made on therapeutic escalation.
authors.affiliation: Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología. gmerino@meditex.es
authors.forename: A
authors.initials: A
authors.lastname: García Merino
authors.forename: O
authors.initials: O
authors.lastname: Fernández
authors.forename: X
authors.initials: X
authors.lastname: Montalbán
authors.forename: C
authors.initials: C
authors.lastname: de Andrés
authors.forename: T
authors.initials: T
authors.lastname: Arbizu
mesh_terms: D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D032921:Consensus; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D009462:Neurology; D012952:Societies; D013030:Spain
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents